Foamix granted US Patent for PerFoam lice treatment

Foamix Ltd., the Israeli speciality pharma company, announced on 12 March 2012 that they had been granted a US patent for their PerFoam head lice treatment.

Foamix specialises in topical foam and gel formulations for dermatology and wound applications. Their PerFoam One treatment comprises an emollient with 1% permethrin and two proprietary enhancers. Clinical trials in 56 children have found it to have a greater than 96% efficacy rate, with no side effects reported.